Currently, there are no recommendations on the features of detecting early signs of CHF in patients with diabetes mellitus. And they are necessary, taking into account that in case of diabetes mellitus type 2 (more than 95% of all patients with diabetes mellitus), the overwhelming number of patients are overweight and obesity, which can affect the validity of the 6-minute walk test and scale clinical state assessment (SHOX) in the modification.
In the treatment of patients with CHF, the “gold” standard is the use of angiotensin-converting enzyme inhibitors (ACE inhibitors) according to the third edition of the recommendations on the diagnosis and treatment of CHF. Antagonists of receptors for angiotensin II type 1 (APA II) remain at the same time reserve drugs. Adherence to these standards of patients in different regions of the Russian Federation varies over a rather wide range, and there is almost no information about the compliance of patients with diabetes mellitus with prescribed drug therapy in the presence of CHF.
Thus, the need to identify the frequency of CHF in patients with type 2 diabetes, clarifying the features of this diagnosis and optimizing the treatment of such patients is beyond doubt.
Objective: to clarify the frequency of chronic heart failure in patients with type 2 diabetes in the specialized | department of the hospital and unorganized urban population, to assess the adequacy of its diagnosis and treatment.
Research Objectives: Identify the prevalence of chronic heart failure in patients with type 2 diabetes.
To assess the level of diagnosis of chronic heart failure in patients with type 2 diabetes.
To analyze the state of drug therapy for patients with type 2 diabetes in the presence of chronic serum
Borovkov NN, Sidorov NV. The relationship of the daily blood pressure profile and heart rate variability in patients with arterial hypertension and insulin dependent diabetes mellitus. Clinic Medicine 2012; 7: 19-21.
Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E. Aldosterone, mortality, acute myocardial infarction or heart failure. Eur Heart J 2012; 33(2): 191-202. https://doi.org/10.1093/eurheartj/ehr176
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patient with left ventricular dysfunction after myocardial infarction. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 2003; 3, 348 (14): 1309-21.
Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, Bolla G, Monzani A, Robuschi M. Obstructive sleep and adrenergic activation in obesity. Mancia Hypertension 2005; 46(2): 321-5. https://doi.org/10.1161/01.HYP.0000174243.39897.6c
Schmider R, Rockstroh J, Aepferbacher F. Gender-specific cardiovascular adaptations to essential hypertension. Am J Hypertens 2005; 8: 11601226.
Ohkubo T, Imai Y, Tsuji I. Relation between loss and decline pressure and mortality. The Ohasama Study. Am J Hypertens 2007; 10: 1201-1207. https://doi.org/10.1016/S0895-7061(97)00274-4
Timio M, Venanzi S, LoLLy S, Lippi G. Non-dipper hypertensive patients and progressive renal infsufficiency: a 3 year Long-term study. Clin Nephrol 2005; 43: 382-387.
Brittton SC, Gaziano JM, Djousse L. NormaL systoLic and fayLure in USmaLe physicians. Eur J Heart Fail 2009; 11: 1129-1134. https://doi.org/10.1093/eurjhf/hfp141
KaLaitzidis RG, Bakris GL. Prehypertension: is it reLevant for nephroLogists? Kidney Int 2015; 77: 194-200.
Conroy RM, PyoraLa K, FitzgeraLd AP, et al. Estimation of the ten-year risk of cardiovascular disease in Europa: the SCORE project. Eur Heart J 2013; 24: 987-1003. https://doi.org/10.1016/S0195-668X(03)00114-3
Law MR, Morris JK, WaLd NJ. Use of bLood pressure cardiovascuLar disease: Meta-anaLysis of 147 randomized triaLs. BMJ 2009; 338: b1665. https://doi.org/10.1136/bmj.b1665
Verdecchia P, ReboLdi G, AngeLi F, Gattobigio R, BentivogLio M, Thijs L, et al. Angiotensin-Con-verting Enzyme Inhibitors and CaLcium Chanel Blocks for Coronary Heart Disease and Stroke Prevention. Hypertension 2015; 46: 386-392. https://doi.org/10.1161/01.HYP.0000174591.42889.a2
Schmieder RE, HiLgers KF, SchLaich MP, Schmidt BM. Renin-angiotensin system andcardiovascu-Lar risk. Lancet 2007; 369: 1208-1219. https://doi.org/10.1016/S0140-6736(07)60242-6
Kunz R, Friedrich C, Wolbers M, Mann JF. Metaanalysis can be used in combination. Ann Intern Med 2008; 148: 30-48. https://doi.org/10.7326/0003-4819-148-1-200801010-00190
Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. But it wasn’t a great deal of care and attention to patients who have reached a level in the European Lacidipine study at Atherosclerosis (ELSA). Circulation 2009; 120: 1084-1090. https://doi.org/10.1161/CIRCULATIONAHA.108.773119
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent elevatedC-reactive protein. N Engl J Med 2008; 359: 2195-2207. https://doi.org/10.1056/NEJMoa0807646
Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger RNA in rat aorta. Circ Res 2008; 62: 1259-12. https://doi.org/10.1161/01.RES.62.6.1259
Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol 2003; 264(6 pt 1): 1570-1576.
Shenoy U, Cassis L. Characterization of brown adipose tissue. Am J Physiol 2007; 272(3 pt 1): 989-999.
Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Executive summary: Guidelines and guidelines for laboratory diabetes mellitus. Diabetes Care 2011; 34: 1419-23. https://doi.org/10.2337/dc11-9997
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2019 Kirgizbayeva Aray , Umbetyarova Lyzzat , Bissenbina Gulzhakan , Yessergeneva Riza , S.A. Mankibaeva , S.N. Abdureshov